# Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure

> **NCT05870709** · — · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Heart Failure

## Interventions

- **OTHER:** sacubitril/valsartan

## Key facts

- **NCT ID:** NCT05870709
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-05-15
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Terminated due to business decision
- **Last updated:** 2023-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05870709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05870709, "Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05870709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*